

Form 51-102F3
Material Change Report

1. Name and Address of Company

AREV Life Sciences Global Corp. (the "Company")

2. Date of Material Change

April 19, 2022

3. News Release

A press release was issued on April 19, 2022 and disseminated through Market News and Stockwatch.

4. Summary of the Material Change

Brian V. Elliott Joins Arev Life Sciences Global Corporation.

5. Full Description of the Material Change

VANCOUVER, BC / April 19, 2022 / AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) ("AREV" or the "Company") AREV Life Sciences Global Corporation announced today the appointment of Brian V. Elliott, B Comm to its Board of Directors.

In the pursuit of innovative global health solutions, AREV Life Sciences Global Corporation adds Brian V. Elliott, among its Board of Directors.

Brian V. Elliott is an international strategist and leader exhibiting over 35 years in Senior Management positions in the pharmaceutical industry and the health related public sectors. He has provided 10 years of service with the Irish Government Industrial Development Authority in Ireland, France, and Lesotho.

Brian entered the pharmaceutical industry holding the position of International Sales Director with Norton Healthcare Generics based in Ireland and the UK directing their Ireland-based manufacturing operations. He assumed the position of Director of Janssen Pharmaceutica NV with responsibility for China, and subsequently was appointed International Trade Director, Janssen Africa, Middle East, West Asia.

He was recruited by Belgian biotech company Tibotec-Virco NV, as Senior Vice President, Corporate Alliances and Business Development. Brian also served as CEO of Tibotec Virco, Ireland.

Brian V. Elliott established Axios International Consultants Ltd in Ireland, and was Chairman of the organization for 5 years during which he undertook many developing country health related projects including:

- United Nations Programme on HIV/AIDS (UNAIDS) negotiator with pharma industry on access to antiretrovirals, where he co-designed the UNAIDS Drug Access Initiative and established pilot projects in Vietnam, Chile, Uganda, and Cote d'Ivoire.
- Advisor to the Danish Government Overseas Aid Ministry on International HIV/AIDS policy.
- The design and implementation of several global access initiatives including:

- Bristol Myers Squibb - Secure the Future project in South Africa,
- Abbott - Step Forward for Children project in Tanzania and Burkina Faso, Abbott
- Gilead - Global Viread donation programme
- Pfizer - diflucan donation project Pfizer
- Roche- Blue Skies project in Southern Africa
- Glaxo Wellcome- tiered pricing for developing countries.

In 2008 Brian was appointed Executive Director of The Medical Transparency Alliance (MeTA), an alliance of the Department for International Development- UK, World Bank, and World Health Organization (WHO) aimed at increasing access to essential medicines in 7 pilot countries (Peru, Jordan, Kyrgyzstan, Uganda, Zambia, Ghana and The Philippines). He also served as a member of the Affordable Medicine Facility for Malaria (AMFm) Expert Advisory Panel on review of the project evaluation process.

Recently, Brian works advising a number of major pharmaceutical companies establishing programs to provide global access to medicines working closely with Johnson & Johnson Global Public Health Group and other multinational companies. These efforts include reporting to companies, agencies and foundations on critical aspects of HIV/AIDS treatment in developing countries.

Projects in these areas include: working closely with Indian manufacturers of antiretroviral drugs to advocate with Global Fund and PEPFAR to modify their procurement processes, reporting. for United Nations Industrial Development Organization (UNIDO), UNAIDS, and WHO on the security of supply of HIV/AIDS commodities, reviewing the Appropriate Use Criteria program (AUC)/ UNIDO Pharmaceutical Manufacturing Plan for Africa for WHO, and providing strategies for implementation of the Pharmaceutical Manufacturing Plan for Africa for WHO/UNIDO.

Brian continues advising Johnson & Johnson Global Public Health Group and several other international pharmaceutical companies on the establishment of Global Access to Medicine programs in developing countries. He compiled the WHO Procurement and Supply Management (PSM) profile update, which updated the PSM profiles for 85 countries enabling assessment of the deployment status of CD4 and VL technology.

He addressed the special UN Assembly meeting on the looming crisis in HIV treatment and formed and advised a coalition of 11 Indian Generic Pharmaceutical Manufacturers and led discussions between them, the President's Emergency Plan for AIDS Relief (PEPFAR), and The Global Fund to address the perceived inequities in the procurement system for antiretrovirals in lower- and middle- income countries, the market dynamics, and risk of security of supply.

He is currently managing the establishment of clinical trials of 2 novel drug drugs to treat NCDs and 2 Covid vaccine candidates in Kenya and advising governments in sub-Saharan Africa.

Further, the Company is pleased to announce that the Company has issued 150,000 stock options to Directors, Officers and Consultants of the Company at a price of \$0.22 for a period of 5 years from the issuance dated. These options will vest immediately.

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51 – 102

Not applicable.

7. Omitted Information

Not applicable.

8. **Executive Officer**
Mike Withrow,
CEO and Director
Phone: (778) 379-8551

9. **Date of Report**
April 19, 2022